Last updated: March 13, 2026
What is NDC 70000-0660?
NDC 70000-0660 corresponds to Doxil (liposomal doxorubicin), an anticancer agent primarily used to treat ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. It is a liposomal formulation designed to improve drug delivery and reduce systemic toxicity compared to conventional doxorubicin.
Market Size and Demand Drivers
Current Market Landscape
The global oncology drug market, including doxorubicin formulations, is valued at approximately $23 billion in 2022, with expected compound annual growth rate (CAGR) of 8% until 2030 [1]. Doxil accounts for a significant share within the rare and difficult-to-treat cancers segment.
Market Demand by Indication
- Ovarian Cancer: Estimated incidence around 19,000 new cases annually in the U.S.
- Kaposi's Sarcoma: Predominately affects immunocompromised (HIV/AIDS). U.S. prevalence about 10,000 cases.
- Multiple Myeloma: Approximate incidence of 34,000 new cases in the U.S. annually.
Competitive Landscape
Doxil faces competition from other liposomal and non-liposomal doxorubicin formulations, including generic doxorubicin hydrochloride and specialty products like Liposomal Doxorubicin (generic versions). Biosimilars and emerging targeted therapies threaten market share.
Pricing History and Projections
Historical Pricing Data
- In 2012, Doxil’s average wholesale price (AWP) in the U.S. was approximately $3,200 per 50 mg vial.
- Since then, the price has fluctuated due to market dynamics, patent expirations, and generic entries.
Price Trends and Influencing Factors
- Patent Litigation & Expiry: Doxil's patent expired in 2018, leading to increased generic competition, lowering prices.
- Regulatory Actions: FDA approvals of biosimilars or competing formulations influence pricing.
Projected Pricing Outlook (2023-2030)
| Year |
Estimated Average Price per Vial (50 mg) |
Notes |
| 2023 |
$1,500 - $2,000 |
Competitive pressure from generics |
| 2025 |
$1,200 - $1,700 |
Market stabilization, biosimilar expansion |
| 2030 |
$1,000 - $1,300 |
Increased generic penetration, price erosion |
Expected Market Penetration
- Generics are anticipated to capture over 70% of the market by 2025.
- Production costs for biosimilars will constrain price reductions further.
- Payers’ negotiations and formulary placements will impact accessible prices.
Regulatory and Policy Influences
- FDA Approvals: Biosimilar approvals can accelerate price declines.
- Reimbursement Policies: U.S. Medicare and Medicaid policies favor lower-cost alternatives.
- International Markets: Low-to-middle income countries will see more aggressive price reductions due to cost constraints.
Investment and R&D Outlook
- Market players are investing in next-generation liposomal formulations aimed at reducing toxicity and improving efficacy.
- Competitive innovations may alter pricing structures and expand indications, impacting market size.
Key Takeaways
- The Doxil market is shrinking due to patent expiration and generic competition.
- Prices are expected to decline steadily over the next decade, with 50 mg vial prices potentially dropping 30-50%.
- The significant share of biosimilars and generics poses downward pressure on pricing.
- The size of the market remains substantial due to ongoing use in multiple cancer indications, although growth may slow.
- Regulatory developments and policy changes will influence market access and pricing strategies.
FAQs
1. How does the patent status influence Doxil's prices?
Patent expiration in 2018 facilitated generic entry, causing price reductions and eroding market share.
2. What are the main competitors to NDC 70000-0660?
Generic liposomal doxorubicin, biosimilars, and alternative chemotherapy agents.
3. When can the market expect further price declines?
Prices are projected to decrease gradually through 2030, with significant reductions by 2025 due to increased biosimilar competition.
4. How does biosimilar approval impact R&D investments?
Approval of biosimilars shifts focus towards developing next-generation formulations or combination therapies to maintain market relevance.
5. What is the future outlook for Doxil's therapeutic indications?
Research into new indications and formulation improvements may sustain demand, but market size growth is expected to slow.
References
[1] Market Research Future. (2022). Oncology drugs market size, share, and forecast. Retrieved from https://www.marketresearchfuture.com
[2] IQVIA. (2022). U.S. Pharmacy Market Data.
[3] U.S. Food and Drug Administration. (2022). Biosimilar and Interchangeable Products Market Reports.
